Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | — | $20,000 | — |
| Operating expenses | ||||
| Research and development | 51,414 | 22,680 | 84,130 | 42,252 |
| Selling, general and administrative | 9,392 | 6,816 | 20,891 | 14,352 |
| Total operating expenses | 60,806 | 29,496 | 105,021 | 56,604 |
| Loss from operations | (60,806) | (29,496) | (85,021) | (56,604) |
| Other income: | ||||
| Interest income | 4,191 | 2,764 | 8,549 | 5,809 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s R&D?
- Rapport Therapeutics, Inc. (RAPP) reported R&D of $51.41M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s R&D changed year-over-year?
- Rapport Therapeutics, Inc.'s R&D increased by 126.7% year-over-year, from $22.68M to $51.41M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s R&D?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s R&D has grown at a 84.0% compound annual growth rate (CAGR), from $28M to $94.79M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Rapport Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude